JP6697386B2 - 改変された高親和性ヒトｔ細胞受容体 - Google Patents

改変された高親和性ヒトｔ細胞受容体 Download PDF

Info

Publication number
JP6697386B2
JP6697386B2 JP2016533163A JP2016533163A JP6697386B2 JP 6697386 B2 JP6697386 B2 JP 6697386B2 JP 2016533163 A JP2016533163 A JP 2016533163A JP 2016533163 A JP2016533163 A JP 2016533163A JP 6697386 B2 JP6697386 B2 JP 6697386B2
Authority
JP
Japan
Prior art keywords
tcr
cell
modified
cell receptor
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2016533163A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017501130A5 (enExample
JP2017501130A (ja
Inventor
シーナ エヌ． スミス，
シーナ エヌ． スミス，
ダニエル ティー． ハリス，
ダニエル ティー． ハリス，
デイビッド エム． クランツ，
デイビッド エム． クランツ，
トーマス エム． シュミット，
トーマス エム． シュミット，
フィリップ ディー． グリーンバーグ，
フィリップ ディー． グリーンバーグ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Illinois System
Original Assignee
University of Illinois System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Illinois System filed Critical University of Illinois System
Publication of JP2017501130A publication Critical patent/JP2017501130A/ja
Publication of JP2017501130A5 publication Critical patent/JP2017501130A5/ja
Priority to JP2019190139A priority Critical patent/JP6970724B2/ja
Application granted granted Critical
Publication of JP6697386B2 publication Critical patent/JP6697386B2/ja
Priority to JP2021178468A priority patent/JP2022023196A/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2016533163A 2013-11-22 2014-11-21 改変された高親和性ヒトｔ細胞受容体 Expired - Fee Related JP6697386B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2019190139A JP6970724B2 (ja) 2013-11-22 2019-10-17 改変された高親和性ヒトｔ細胞受容体
JP2021178468A JP2022023196A (ja) 2013-11-22 2021-11-01 改変された高親和性ヒトｔ細胞受容体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361907887P 2013-11-22 2013-11-22
US61/907,887 2013-11-22
PCT/US2014/066903 WO2015077615A1 (en) 2013-11-22 2014-11-21 Engineered high-affinity human t cell receptors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019190139A Division JP6970724B2 (ja) 2013-11-22 2019-10-17 改変された高親和性ヒトｔ細胞受容体

Publications (3)

Publication Number Publication Date
JP2017501130A JP2017501130A (ja) 2017-01-12
JP2017501130A5 JP2017501130A5 (enExample) 2017-12-21
JP6697386B2 true JP6697386B2 (ja) 2020-05-20

Family

ID=53180203

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2016533163A Expired - Fee Related JP6697386B2 (ja) 2013-11-22 2014-11-21 改変された高親和性ヒトｔ細胞受容体
JP2016533150A Active JP6476182B2 (ja) 2013-11-22 2014-11-21 改変された高親和性ヒトｔ細胞受容体
JP2019190139A Expired - Fee Related JP6970724B2 (ja) 2013-11-22 2019-10-17 改変された高親和性ヒトｔ細胞受容体
JP2021178468A Pending JP2022023196A (ja) 2013-11-22 2021-11-01 改変された高親和性ヒトｔ細胞受容体

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2016533150A Active JP6476182B2 (ja) 2013-11-22 2014-11-21 改変された高親和性ヒトｔ細胞受容体
JP2019190139A Expired - Fee Related JP6970724B2 (ja) 2013-11-22 2019-10-17 改変された高親和性ヒトｔ細胞受容体
JP2021178468A Pending JP2022023196A (ja) 2013-11-22 2021-11-01 改変された高親和性ヒトｔ細胞受容体

Country Status (20)

Country Link
US (4) US10023625B2 (enExample)
EP (2) EP3071593B1 (enExample)
JP (4) JP6697386B2 (enExample)
KR (2) KR20160085345A (enExample)
CN (2) CN105873945B (enExample)
AU (4) AU2014352826B2 (enExample)
BR (1) BR112016011567A2 (enExample)
CA (2) CA2930852C (enExample)
DK (1) DK3071593T3 (enExample)
ES (1) ES2729406T3 (enExample)
IL (2) IL245467B (enExample)
MX (3) MX371202B (enExample)
PL (1) PL3071593T3 (enExample)
PT (1) PT3071593T (enExample)
RU (2) RU2729383C2 (enExample)
SA (1) SA516371174B1 (enExample)
SG (2) SG10201804335QA (enExample)
TR (1) TR201908404T4 (enExample)
WO (2) WO2015077607A1 (enExample)
ZA (2) ZA201603116B (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2565201B1 (en) 2005-10-17 2014-11-26 Sloan-Kettering Institute For Cancer Research WT1 HLA class II-binding peptides and compositions and methods comprising same
EP2010209B1 (en) 2006-04-10 2016-06-15 Sloan Kettering Institute For Cancer Research Immunogenic wt-1 peptides and methods of use thereof
CN104684577B (zh) 2012-01-13 2018-05-08 纪念斯隆凯特林癌症中心 免疫原性wt-1肽及其使用方法
ES2832546T3 (es) 2013-01-15 2021-06-10 Memorial Sloan Kettering Cancer Center Péptidos WT-1 inmunogénicos y métodos de uso de los mismos
US10815273B2 (en) 2013-01-15 2020-10-27 Memorial Sloan Kettering Cancer Center Immunogenic WT-1 peptides and methods of use thereof
BR112016011567A2 (pt) * 2013-11-22 2017-10-24 Hutchinson Fred Cancer Res receptores de célula t humana de alta afinidade geneticamente modificados.
WO2017050884A1 (en) * 2015-09-22 2017-03-30 Julius-Maximilians-Universität Würzburg A method for high level and stable gene transfer in lymphocytes
AU2016329542C1 (en) * 2015-10-01 2023-11-23 Fondazione Centro San Raffaele TCR and uses thereof
GB201520570D0 (en) * 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
US11026969B2 (en) 2015-12-23 2021-06-08 Fred Hutchinson Cancer Research Center High affinity T cell receptors and uses thereof
MA45491A (fr) * 2016-06-27 2019-05-01 Juno Therapeutics Inc Épitopes à restriction cmh-e, molécules de liaison et procédés et utilisations associés
RU2019116312A (ru) * 2016-11-14 2020-12-14 Фред Хатчинсон Кэнсер Рисерч Сентер Высокоаффинные tcr, специфичные к t-антигену полиомавируса клеток меркеля, и их применения
CA3055983A1 (en) * 2017-03-15 2018-09-20 Fred Hutchinson Cancer Research Center High affinity mage-a1-specific tcrs and uses thereof
AU2018259029B2 (en) * 2017-04-24 2024-03-07 Fondazione Centro San Raffaele TCR and peptides
JP7181517B2 (ja) * 2018-01-23 2022-12-01 国立大学法人三重大学 Ｔ細胞レセプター
CN112739339B (zh) * 2018-07-23 2024-12-27 海德堡医药研究有限责任公司 抗cd137抗体药物缀合物(adc)在同种异体细胞疗法中的用途
US12448430B2 (en) 2019-03-11 2025-10-21 Fred Hutchinson Cancer Center High avidity WT1 T cell receptors and uses thereof
GB201911066D0 (en) 2019-08-02 2019-09-18 Achilles Therapeutics Ltd T cell therapy
WO2021034976A1 (en) * 2019-08-20 2021-02-25 Fred Hutchinson Cancer Research Center T-cell immunotherapy specific for wt-1
BR112022015982A2 (pt) * 2020-02-12 2022-10-11 Abbvie Inc Moléculas de ligação bispecíficas
WO2021219990A1 (en) 2020-04-28 2021-11-04 Achilles Therapeutics Uk Limited T cell therapy
CN112239495B (zh) * 2020-10-29 2022-04-12 上海药明生物技术有限公司 稳定的tcr结构及应用
GB202109886D0 (en) 2021-07-08 2021-08-25 Achilles Therapeutics Uk Ltd Assay
EP4320435A1 (en) 2021-04-09 2024-02-14 Achilles Therapeutics UK Limited Batch release assay for pharmaceutical products relating to t cell therapies
CA3223074A1 (en) 2021-06-22 2022-12-29 Achilles Therapeutics Uk Limited A method for producing antigen specific t cells
MX2024000941A (es) * 2021-07-19 2024-04-18 Univ Texas Péptidos y receptores manipulados de linfocitos t dirigidos a antígenos fanci, rad51 y pbk y métodos de uso.
CN119220425A (zh) * 2023-07-28 2024-12-31 佳吾益(北京)科技有限公司 发现mhc新抗原肽表位的工程化细胞

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3927193A (en) 1973-05-18 1975-12-16 Hoffmann La Roche Localization of tumors by radiolabelled antibodies
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4348376A (en) 1980-03-03 1982-09-07 Goldenberg Milton David Tumor localization and therapy with labeled anti-CEA antibody
US4444744A (en) 1980-03-03 1984-04-24 Goldenberg Milton David Tumor localization and therapy with labeled antibodies to cell surface antigens
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4361544A (en) 1980-03-03 1982-11-30 Goldenberg Milton David Tumor localization and therapy with labeled antibodies specific to intracellular tumor-associated markers
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4468457A (en) 1981-06-01 1984-08-28 David M. Goldenberg Method for producing a CSAp tryptic peptide and anti-CSAp antibodies
US5101827A (en) 1985-07-05 1992-04-07 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US4640561A (en) 1985-11-15 1987-02-03 Ford Motor Company Flexible printed circuit connector
US5059413A (en) 1988-04-18 1991-10-22 Xoma Corporation Scintigraphic monitoring of immunotoxins using radionuclides and heterobifunctional chelators
AU650629B2 (en) 1989-08-09 1994-06-30 Rhomed Incorporated Direct radiolabeling of antibodies and other proteins with technetium or rhenium
US5299253A (en) 1992-04-10 1994-03-29 Akzo N.V. Alignment system to overlay abdominal computer aided tomography and magnetic resonance anatomy with single photon emission tomography
US6300065B1 (en) 1996-05-31 2001-10-09 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
US6696251B1 (en) 1996-05-31 2004-02-24 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
US6699658B1 (en) 1996-05-31 2004-03-02 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
US6759243B2 (en) 1998-01-20 2004-07-06 Board Of Trustees Of The University Of Illinois High affinity TCR proteins and methods
ID28040A (id) 1998-05-19 2001-05-03 Avidex Ltd Reseptor sel t yang dapat larut
EP1124568B1 (en) 1998-10-21 2007-08-22 Altor BioScience Corporation Polyspecific binding molecules and uses thereof
AU2002321581C1 (en) 2001-08-31 2008-09-18 Adaptimmune Limited Soluble T cell receptor
US7892559B2 (en) 2002-01-30 2011-02-22 Survac Aps Survivin-derived peptides and use thereof
AU2003271904B2 (en) 2002-10-09 2009-03-05 Adaptimmune Limited Single chain recombinant T cell receptors
GB0304068D0 (en) 2003-02-22 2003-03-26 Avidex Ltd Substances
GB0328363D0 (en) * 2003-12-06 2004-01-14 Imp College Innovations Ltd Therapeutically useful molecules
ATE417065T1 (de) 2004-05-19 2008-12-15 Medigene Ltd Hochaffiner ny-eso-t-zellen-rezeptor
DE602005009825D1 (de) 2004-05-19 2008-10-30 Medigene Ltd Verfahren zur verbesserung von t-zellrezeptoren
GB0524477D0 (en) 2005-11-30 2006-01-11 Avidex Ltd Isolated T cell receptors which specifically bind to vygfvracl-hla-24
GB0511124D0 (en) 2005-06-01 2005-07-06 Avidex Ltd High affinity melan-a t cell receptors
AT503861B1 (de) 2006-07-05 2008-06-15 F Star Biotech Forsch & Entw Verfahren zur manipulation von t-zell-rezeptoren
WO2008039818A2 (en) 2006-09-26 2008-04-03 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Modified t cell receptors and related materials and methods
US9281917B2 (en) 2007-01-03 2016-03-08 Nokia Technologies Oy Shared control channel structure
CN102272153B (zh) * 2008-11-24 2015-04-15 德国慕尼黑亥姆霍兹研究中心健康和环境有限公司 高亲和力t细胞受体及其应用
WO2010075417A1 (en) * 2008-12-23 2010-07-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Survivin specific t cell receptor for treating cancer
AU2010210083C1 (en) * 2009-02-09 2015-11-26 Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Fuer Gesundheit Und Umwelt (Gmbh) Repertoire of allo-restricted peptide-specific T cell receptor sequences and use thereof
GB0911566D0 (en) 2009-07-03 2009-08-12 Immunocore Ltd T cell receptors
US10464987B2 (en) 2009-10-06 2019-11-05 Abbvie Inc. Human single-chain T cell receptors
BR112013003647A2 (pt) 2010-07-28 2017-11-07 Immunocore Ltd receptores de células t.
US9586997B2 (en) 2010-09-20 2017-03-07 Biontech Cell & Gene Therapies Gmbh Antigen-specific T cell receptors and T cell epitopes
CN107557334B (zh) 2012-05-03 2021-06-25 弗雷德哈钦森癌症研究中心 增强亲和力的t细胞受体及其制备方法
WO2014191465A1 (en) * 2013-05-28 2014-12-04 Møller Niels Iversen Peptides derived from lawsonia intracellularis and their use in vaccination
PL228457B1 (pl) 2013-08-30 2018-03-30 Univ Jagiellonski Tomograf hybrydowy TOF-PET/CT
BR112016011567A2 (pt) 2013-11-22 2017-10-24 Hutchinson Fred Cancer Res receptores de célula t humana de alta afinidade geneticamente modificados.
ES2841274T3 (es) * 2014-08-04 2021-07-07 Hutchinson Fred Cancer Res Inmunoterapia con células T específica para WT-1
CN113105562B (zh) * 2018-09-26 2023-12-01 安源医药科技（上海）有限公司 突变型单链人凝血因子viii在制备融合蛋白中的应用

Also Published As

Publication number Publication date
SG10201804335QA (en) 2018-06-28
CN105873945A (zh) 2016-08-17
CA2930852C (en) 2024-01-23
JP2022023196A (ja) 2022-02-07
EP3071593A4 (en) 2017-05-03
RU2729383C2 (ru) 2020-08-06
SA516371174B1 (ar) 2019-04-14
US10344075B2 (en) 2019-07-09
CN105873945B (zh) 2020-07-17
IL245467A0 (en) 2016-06-30
IL245467B (en) 2020-04-30
MX2021006932A (es) 2021-07-07
EP3071594A1 (en) 2016-09-28
SG10201804330YA (en) 2018-07-30
KR20160085345A (ko) 2016-07-15
CA2930852A1 (en) 2015-05-28
WO2015077615A1 (en) 2015-05-28
MX371202B (es) 2020-01-22
US10023625B2 (en) 2018-07-17
AU2021202274A1 (en) 2021-05-06
US20160280755A1 (en) 2016-09-29
IL245468A0 (en) 2016-06-30
EP3071593A1 (en) 2016-09-28
CN105899530A (zh) 2016-08-24
WO2015077607A1 (en) 2015-05-28
CA2930847A1 (en) 2015-05-28
US20190055298A1 (en) 2019-02-21
AU2014352834B2 (en) 2019-08-29
KR20160087866A (ko) 2016-07-22
US20220396606A1 (en) 2022-12-15
IL245468B (en) 2020-10-29
AU2019272003A1 (en) 2019-12-19
TR201908404T4 (tr) 2019-07-22
NZ719720A (en) 2020-09-25
RU2016124179A (ru) 2017-12-27
US20160280756A1 (en) 2016-09-29
EP3071594A4 (en) 2017-05-03
PL3071593T3 (pl) 2019-11-29
DK3071593T3 (da) 2019-06-11
AU2014352826A1 (en) 2016-05-26
KR102415259B1 (ko) 2022-06-30
MX2016006620A (es) 2017-05-11
JP6476182B2 (ja) 2019-02-27
JP6970724B2 (ja) 2021-11-24
ZA201603116B (en) 2018-12-19
AU2019272003B2 (en) 2021-05-06
EP3071593B1 (en) 2019-03-13
ES2729406T3 (es) 2019-11-04
CN105899530B (zh) 2020-05-08
NZ719707A (en) 2020-09-25
MX383471B (es) 2025-03-14
BR112016011567A2 (pt) 2017-10-24
AU2014352826B2 (en) 2019-08-01
AU2014352834A1 (en) 2016-05-26
JP2017501129A (ja) 2017-01-12
RU2016124163A (ru) 2017-12-27
ZA201603169B (en) 2020-05-27
RU2740648C2 (ru) 2021-01-19
JP2017501130A (ja) 2017-01-12
PT3071593T (pt) 2019-06-27
MX2016006625A (es) 2016-12-02
BR112016011583A2 (pt) 2017-09-26
JP2020007374A (ja) 2020-01-16

Similar Documents

Publication Publication Date Title
JP6697386B2 (ja) 改変された高親和性ヒトｔ細胞受容体
US11384133B2 (en) Engineering t cell receptors
NZ719720B2 (en) Engineered human t cell receptors with high affinity for wt1
HK1228412B (en) Engineered high-affinity human t cell receptors
HK1228412A1 (en) Engineered high-affinity human t cell receptors
NZ719707B2 (en) Engineered human t cell receptors with high affinity for binding survivin

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171113

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20171113

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20180906

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20181004

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20181227

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190301

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190403

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190422

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190719

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190917

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191017

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200327

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200424

R150 Certificate of patent or registration of utility model

Ref document number: 6697386

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees